- Home
- CDNA vs NRK Comparison
CDNA vs NRK Comparison
Compare CDNA & NRK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CDNA
- NRK
- Stock Information
- Founded
- CDNA 1998
- NRK 2002
- Country
- CDNA United States
- NRK United States
- Employees
- CDNA N/A
- NRK N/A
- Industry
- CDNA Medical Specialities
- NRK Trusts Except Educational Religious and Charitable
- Sector
- CDNA Health Care
- NRK Finance
- Exchange
- CDNA Nasdaq
- NRK Nasdaq
- Market Cap
- CDNA 712.2M
- NRK 824.4M
- IPO Year
- CDNA 2014
- NRK N/A
- Fundamental
- Price
- CDNA $15.19
- NRK $10.16
- Analyst Decision
- CDNA Buy
- NRK
- Analyst Count
- CDNA 8
- NRK 0
- Target Price
- CDNA $26.86
- NRK N/A
- AVG Volume (30 Days)
- CDNA 1.3M
- NRK 187.3K
- Earning Date
- CDNA 11-03-2025
- NRK 01-01-0001
- Dividend Yield
- CDNA N/A
- NRK 4.10%
- EPS Growth
- CDNA N/A
- NRK N/A
- EPS
- CDNA 1.00
- NRK N/A
- Revenue
- CDNA $340,826,000.00
- NRK N/A
- Revenue This Year
- CDNA $12.73
- NRK N/A
- Revenue Next Year
- CDNA $11.90
- NRK N/A
- P/E Ratio
- CDNA $15.23
- NRK N/A
- Revenue Growth
- CDNA 14.72
- NRK N/A
- 52 Week Low
- CDNA $10.96
- NRK $8.95
- 52 Week High
- CDNA $32.76
- NRK $11.09
- Technical
- Relative Strength Index (RSI)
- CDNA 60.38
- NRK 67.58
- Support Level
- CDNA $14.28
- NRK $10.06
- Resistance Level
- CDNA $15.21
- NRK $10.29
- Average True Range (ATR)
- CDNA 0.60
- NRK 0.09
- MACD
- CDNA 0.02
- NRK 0.00
- Stochastic Oscillator
- CDNA 72.48
- NRK 61.43
About CDNA CareDx Inc.
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically the company generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.
About NRK Nuveen New York AMT-Free Quality Municipal Income Fund
Nuveen New York AMT-Free Quality Municipal Income Fund is a closed-end investment company. Its investment objective is to provide current income exempt from regular federal, New York State, and New York City income taxes and from the federal alternative minimum tax applies to individuals and to enhance portfolio value relative to the municipal bond market by investing in tax-exempt municipal bonds that the Fund's investment adviser believes are underrated or undervalued or that represent municipal market sectors that are undervalued.